

ICMJE DISCLOSURE FORM

Date: 7/25/2022

Your Name: Michiel Coppens

Manuscript Title: Antifosfolipiden syndroom – diagnostiek en behandeling in de context van een veneuze trombo-embolie

Manuscript Number (if known): [Click or tap here to enter text.](#)

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)												
Time frame: Since the initial planning of the work															
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<input checked="" type="checkbox"/> None <table border="1" style="width: 100%; border-collapse: collapse;"> <tr><td style="height: 20px;"> </td><td style="width: 20%;"> </td></tr> <tr><td style="height: 20px;"> </td><td> </td></tr> <tr><td style="height: 20px;"> </td><td> </td></tr> </table>							<div style="text-align: right; font-size: small; color: #ccc;">Click the tab key to add additional rows.</div>						
Time frame: past 36 months															
2	Grants or contracts from any entity (if not indicated in item #1 above).	<input type="checkbox"/> None <table border="1" style="width: 100%; border-collapse: collapse;"> <tr><td style="width: 60%;">Bayer</td><td>Payments to my institution</td></tr> <tr><td>CSL Behring</td><td>Payments to my institution</td></tr> <tr><td>Daiichi Sankyo</td><td>Payments to my institution</td></tr> <tr><td>Novo Nordisk</td><td>Payments to my institution</td></tr> <tr><td>Roche</td><td>Payments to my institution</td></tr> <tr><td>UniQure</td><td>Payments to my institution</td></tr> </table>	Bayer	Payments to my institution	CSL Behring	Payments to my institution	Daiichi Sankyo	Payments to my institution	Novo Nordisk	Payments to my institution	Roche	Payments to my institution	UniQure	Payments to my institution	
Bayer	Payments to my institution														
CSL Behring	Payments to my institution														
Daiichi Sankyo	Payments to my institution														
Novo Nordisk	Payments to my institution														
Roche	Payments to my institution														
UniQure	Payments to my institution														
3	Royalties or licenses	<input checked="" type="checkbox"/> None <table border="1" style="width: 100%; border-collapse: collapse;"> <tr><td style="height: 20px;"> </td><td> </td></tr> <tr><td style="height: 20px;"> </td><td> </td></tr> <tr><td style="height: 20px;"> </td><td> </td></tr> </table>													

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	<input type="checkbox"/> None	
		CSL Behring	Payments to my institution
		Novo Nordisk	Payments to my institution
		Viartis	Payments to my institution
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input type="checkbox"/> None	
		Alexion	Payments to my institution
		Bayer	Payments to my institution
		CSL Behring	Payments to my institution
		Daiichi Sankyo	Payments to my institution
		Sobi	Payments to my institution
6	Payment for expert testimony	<input checked="" type="checkbox"/> None	
7	Support for attending meetings and/or travel	<input type="checkbox"/> None	
		Alexion	Hotel fee for 2 nights and registration fees for congress
		Sobi	Course for ultrasound in hemophilia
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input type="checkbox"/> None	
		Voorzitter van de werkgroep Trombose van de Nederlandse Vereniging van Internisten Vasculaire Geneeskunde (NVIVG), deelvereniging van de Nederlandse Internisten Vereniging (NIV)	Onbetaald
		Lid van wetenschappelijke adviesraad van Trombosestichting Nederland (TSN)	Onbetaald

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
11	Stock or stock options	<input checked="" type="checkbox"/> None <table border="1" style="width: 100%; border-collapse: collapse;"> <tr><td style="width: 50%; height: 15px;"></td><td style="width: 50%;"></td></tr> <tr><td style="height: 15px;"></td><td></td></tr> <tr><td style="height: 15px;"></td><td></td></tr> </table>							
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None <table border="1" style="width: 100%; border-collapse: collapse;"> <tr><td style="width: 50%; height: 15px;"></td><td style="width: 50%;"></td></tr> <tr><td style="height: 15px;"></td><td></td></tr> <tr><td style="height: 15px;"></td><td></td></tr> </table>							
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None <table border="1" style="width: 100%; border-collapse: collapse;"> <tr><td style="width: 50%; height: 15px;"></td><td style="width: 50%;"></td></tr> <tr><td style="height: 15px;"></td><td></td></tr> <tr><td style="height: 15px;"></td><td></td></tr> </table>							

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.